California Department of Health Services, Division of Communicable Disease Control. (1999). Prevention and control of scabies in California long-term care facilities. Retrieved March 24, 2004, from http://www.dhs.ca.gov/ps/dcdc/disb/pdf/Scabies%20Guide.pdf
2.
Centers for Disease Control and Prevention. (1988, March 25). Epidemiologic notes and reports scabies in health-care facilities—Iowa.Morbidity and Mortality Weekly Report,37(11), 178–179.
3.
Centers for Disease Control and Prevention. (1998, January 23). 1998 guidelines for treatment of sexually transmitted diseases.Morbidity and Mortality Recommendations and Reports, 47(RR-1), 1–118.
4.
FitzpatrickT.B., JohnsonR.A., WolfeK., PolanoM.K., & SuurmondD. (1997). Scabies. In WonsiewiczM.J., EnglisM.R., & McCurdyP.A. (Eds.), Color atlas and synopsis of clinical dermatology (3rd ed., pp. 842–849). New York: McGraw-Hill.
5.
HabifT.P. (2003). Infestations and bites: Scabies. In Clinical dermatology (4th ed., pp. 497–505). Mosby.
ObasanjoO.O., WuP., ConlonM., KaranfilL.V., PryorP., MolerG., AnhaltG., ChaissonR.E., & PerlT.M. (2001). An outbreak of scabies in a teaching hospital: Lessons learned.Infection Control and Hospital Epidemiology, 22(1), 13–18.
8.
ScheinfeldN. (2004). Controlling scabies in institutional settings: A review of medications, treatment models and implementation.American Journal of Clinical Dermatology, 5(1), 31–37.
9.
U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (2003). FDA public health advisory: Safety of topical lindane products for treatment of scabies and lice. Retrieved March 24, 2004, from http://www.fda.gov/cder/drug/infopage/lindane/lindanePHA.htm